Challenges in the value assessment, pricing and funding of targeted combination therapies in oncology

D. Dankó, J-Y. Blay and L.P. Garrison

Health Policy, 2019, vol. 123, issue 12, 1230-1236

Abstract: The use of targeted combination therapy (TCT) is becoming the standard of care in oncology as cancers are attacked through multiple inhibition mechanisms. TCTs pose a budget challenge to health systems and an economic return challenge for companies developing them.

Keywords: Combination therapy; Health technology assessment; Value assessment; Pricing; Funding; Oncology; Hematology; Targeted combinations (search for similar items in EconPapers)
Date: 2019
References: View references in EconPapers View complete reference list from CitEc
Citations: View citations in EconPapers (3)

Downloads: (external link)
http://www.sciencedirect.com/science/article/pii/S0168851018304597
Full text for ScienceDirect subscribers only

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:eee:hepoli:v:123:y:2019:i:12:p:1230-1236

DOI: 10.1016/j.healthpol.2019.07.009

Access Statistics for this article

Health Policy is currently edited by Katrien Kesteloot, Mia Defever and Irina Cleemput

More articles in Health Policy from Elsevier
Bibliographic data for series maintained by Catherine Liu () and ().